SCHEMBL26318648

SCHEMBL26318648

COc1c(Br)ccc(C)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 3/20 0.38
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
TUBB1 Q9H4B7 6/20 0.34
ACHE P22303 1/20 0.33
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
MEN1 O00255 2/20 0.32
MAPT P10636 2/20 0.32
ALOX15 P16050 2/20 0.32
KMT2A Q03164 2/20 0.32
USP2 O75604 1/20 0.32
TUBB4A P04350 3/20 0.32
TUBB P07437 3/20 0.32
TUBA3C P0DPH7 3/20 0.32
TUBA1B P68363 3/20 0.32
TUBA4A P68366 3/20 0.32
TUBB4B P68371 3/20 0.32
TUBB3 Q13509 3/20 0.32
TUBB2A Q13885 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL931100 0.83 CA2 (0.35) NQO2CA2CA4TUBB1MEN1
SCHEMBL14405259 0.81 ALDH1A1 (0.36) TUBB1ACHEMEN1MAPTALOX15
SCHEMBL17797225 0.80 L3MBTL1 (0.40) NQO2CA2CA4TUBB1ALOX5AP
SCHEMBL4922559 0.79 CA2 (0.44) NQO2CA2CA4TUBB1ACHE
SCHEMBL14725631 0.77 NQO2 (0.40) NQO2CA2CA4TUBB1ACHE
SCHEMBL9213947 0.77 CA2 (0.43) NQO2CA2CA4TUBB1ACHE
SCHEMBL9410517 0.77 ALDH1A1 (0.45) MAPTALDH1A1KDM4EMAPK1GAA
SCHEMBL23461762 0.77 ALOX5AP (0.38) NQO2CA2CA4TUBB1ALOX5AP
SCHEMBL3841837 0.77 NQO2 (0.37) NQO2CA2CA4TUBB1ALOX5AP
SCHEMBL10042714 0.76 CYP19A1 (0.40) NQO2TUBB1ACHEMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224249-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 WO disclosed
WO-2025224262-A1 COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 WO disclosed
US-20230301183-A1 ORGANIC LIGHT EMITTING DEVICE LG CHEM, LTD. (KR) 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230301183-A1 ORGANIC LIGHT EMITTING DEVICE CRY1, CRY2, CYP1A1 NQO2 1183/4885CA2 1992/4885CA4 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.